Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

'Death Receptors' Designed To Kill Our Cells May Make Them Stronger
It turns out that from the perspective of cell biology, Nietzsche may have been right after all: that which does not kill us does make us stronger. In a review article published in the June 2009 print issue of The FASEB Journal, scientists from the Mayo Clinic explain how cell receptors (called "death receptors") used by the body to shut down old, diseased, or otherwise unwanted cells (called "apoptosis") may also be used to make cells heartier when facing a wide range of illnesses, from liver disease to cancer.
generic viagra online
UC Davis Grant Zeroes In On Novel Asthma Diagnosis, Treatment
An entomology professor at the University of California, Davis who discovered a novel therapeutic target for treating inflammation, has received a three-year $750,000 grant from the American Asthma Foundation to investigate whether his discovery will work on asthma, a chronic disease affecting 300 million people worldwide, including 23 million Americans.
News of the day
Altair Therapeutics Reports Successful Completion Of Phase I Study Of Inhaled AIR645
Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, reported results from its phase I study evaluating the safety, tolerability and pharmacokinetics of its lead product, once-weekly inhaled AIR645, in healthy volunteers. AIR645 is a non-steroidal dual inhibitor of cellular responses to interleukin (IL)-4 and IL-13, cytokines that play a critical role in development and progression of asthma, rhinitis and other allergic disorders. Results presented today at the 2009 International Conference of the American Thoracic Society (ATS) within the Mini-Symposium "New Treatment Approaches for Asthma and Allergy" showed that inhaled AIR645 was safe, well tolerated and had dose-dependent exposure in the airways. These results demonstrate the potential of AIR645 as a convenient once-weekly treatment for asthma and other respiratory disorders. Later this year, Altair plans to initiate a phase II efficacy study in patients with asthma.
Diagnostics

Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties Of TAK-652 For The Treatment Of HIV

Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two Phase I pharmacokinetic studies for TAK-652, an investigational compound being developed for the treatment of HIV. These data suggest that TAK-652 is rapidly absorbed and demonstrate relatively good oral bioavailability (as shown by the plasma TBR-652 concentration data) and has a long plasma half-life of TBR-652 (approximate mean of 35 hours) supporting once-daily dosing. Mean TBR-652 plasma concentrations were well above the predicted target plasma concentration (2ng/mL) with or without food. In both studies TBR-652 was safe and well tolerated in this healthy subject population when administered over a dose range of 10 mg to 800 mg in 2 tablet formulations. "These two Phase I studies provide encouraging support for TAK-652 as a therapeutic option for the treatment of HIV. We look forward to results from our on-going proof-of-concept study," said James Sapirstein, CEO. About Tobira Therapeutics Inc. Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development. Tobira Therapeutics Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009